{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:10:42Z","timestamp":1789236642751,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the 90th Anniversary of Chulalongkorn University, Rachadapisek Sompote Fund","award":["3\/2562"],"award-info":[{"award-number":["3\/2562"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The objective of this study was to determine the impact of calcium sensing receptor (\n                    <jats:italic>CASR<\/jats:italic>\n                    ) A990G genetic polymorphism on parathyroid hormone (PTH) lowering response to cinacalcet treatment when controlling for significant influencing clinical factors. This retrospective study was conducted on 135 Thai hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT).\n                    <jats:italic>CASR<\/jats:italic>\n                    A990G genotypes were determined. The patients were identified as either G carriers (heterozygous or homozygous\n                    <jats:italic>CASR<\/jats:italic>\n                    990G allele carriers) or noncarriers (homozygous\n                    <jats:italic>CASR<\/jats:italic>\n                    990A carriers). Tested covariates were baseline PTH level (bPTH), baseline serum phosphate (bPhos), baseline serum calcium (bCa), baseline calcitriol equivalent dose (bCtriol), baseline ergocalciferol dose (bErgo), and age. The ANCOVA showed that intact PTH levels after 12\u00a0weeks of cinacalcet treatment (PTHw12) was significantly lower among G carriers compared with noncarriers after controlling for bPTH, bPhos, bCtriol, and bErgo (F(1, 127)\u2009=\u200915.472, p\u2009&lt;\u20090.001), with the adjusted mean difference of 253.7\u00a0pg\/mL. The logistic regression analysis revealed that the odds of a G carrier achieving 30% PTH reduction after 12-week cinacalcet treatment were 3.968 times greater than the odds for a noncarrier after adjusting for bPhos, bCtriol, and age. In conclusion, the\n                    <jats:italic>CASR<\/jats:italic>\n                    A990G polymorphism significantly influences cinacalcet response in HD patients with SHPT.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-97587-8","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T06:06:24Z","timestamp":1631167584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism"],"prefix":"10.1038","volume":"11","author":[{"given":"Jaruwan","family":"Ngamkam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somratai","family":"Vadcharavivad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutthada","family":"Areepium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titinun","family":"Auamnoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kullaya","family":"Takkavatakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisut","family":"Katavetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khajohn","family":"Tiranathanagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kearkiat","family":"Praditpornsilpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Eiam-Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paweena","family":"Susantitaphong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"97587_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/366575a0","volume":"366","author":"EM Brown","year":"1993","unstructured":"Brown, E. M. et al. Cloning and characterization of an extracellular Ca 2+-sensing receptor from bovine parathyroid. Nature 366, 575\u2013580 (1993).","journal-title":"Nature"},{"key":"97587_CR2","doi-asserted-by":"publisher","first-page":"e1001436","DOI":"10.1371\/journal.pmed.1001436","volume":"10","author":"SC Palmer","year":"2013","unstructured":"Palmer, S. C. et al. Cinacalcet in patients with chronic kidney disease: A cumulative meta-analysis of randomized controlled trials. PLoS Med. 10, e1001436 (2013).","journal-title":"PLoS Med."},{"key":"97587_CR3","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham, J., Danese, M., Olson, K., Klassen, P. & Chertow, G. M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 68, 1793\u20131800 (2005).","journal-title":"Kidney Int."},{"key":"97587_CR4","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block, G. A. et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350, 1516\u20131525 (2004).","journal-title":"N. Engl. J. Med."},{"key":"97587_CR5","doi-asserted-by":"publisher","first-page":"e48070","DOI":"10.1371\/journal.pone.0048070","volume":"7","author":"Q Zhang","year":"2012","unstructured":"Zhang, Q. et al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS ONE 7, e48070 (2012).","journal-title":"PLoS ONE"},{"key":"97587_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","volume":"67","author":"SM Moe","year":"2005","unstructured":"Moe, S. M. et al. Achieving NKF-K\/DOQITM bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 67, 760\u2013771 (2005).","journal-title":"Kidney Int."},{"key":"97587_CR7","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/ndt\/gfh966","volume":"20","author":"SM Moe","year":"2005","unstructured":"Moe, S. M. et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol. Dial. Transplant. 20, 2186\u20132193 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"97587_CR8","first-page":"176","volume":"64","author":"P Kuczera","year":"2013","unstructured":"Kuczera, P., Adamczak, M. & Wi\u0119cek, A. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. Endokrynol. Pol. 64, 176\u2013181 (2013).","journal-title":"Endokrynol. Pol."},{"key":"97587_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore, J. B. et al. A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin. J. Am. Soc. Nephrol. 10, 1031\u20131040 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97587_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa, M. et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favourable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol. Dial. Transplant. 23, 328\u2013335 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"97587_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1681\/ASN.2004060512","volume":"16","author":"JS Lindberg","year":"2005","unstructured":"Lindberg, J. S. et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. 16, 800\u2013807 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"97587_CR12","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","volume":"56","author":"E Slatopolsky","year":"1999","unstructured":"Slatopolsky, E., Brown, A. & Dusso, A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 56, S14\u2013S19 (1999).","journal-title":"Kidney Int."},{"key":"97587_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"KDIGO","year":"2017","unstructured":"KDIGO. Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl. 7, 1\u201359 (2017).","journal-title":"Kidney Int. Suppl."},{"key":"97587_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/CJN.12941213","volume":"10","author":"F Tentori","year":"2015","unstructured":"Tentori, F. et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study. Clin. J. Am. Soc. Nephrol. 10, 98\u2013109 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97587_CR15","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block, G. A., Hulbert-Shearon, T. E., Levin, N. W. & Port, F. K. Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. 31, 607\u2013617 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"97587_CR16","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","volume":"35","author":"GA Block","year":"2000","unstructured":"Block, G. A. & Port, F. K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am. J. Kidney Dis. 35, 1226\u20131237 (2000).","journal-title":"Am. J. Kidney Dis."},{"key":"97587_CR17","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1681\/ASN.V12102131","volume":"12","author":"SK Ganesh","year":"2001","unstructured":"Ganesh, S. K., Stack, A. G., Levin, N. W., Hulbert-Shearon, T. & Port, F. K. Association of elevated serum PO4, Ca\u00d7 PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12, 2131\u20132138 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"97587_CR18","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/ndt\/gfv099","volume":"30","author":"JL Fern\u00e1ndez-Mart\u00edn","year":"2015","unstructured":"Fern\u00e1ndez-Mart\u00edn, J. L. et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: The COSMOS study. Nephrol. Dial. Transplant. 30, 1542\u20131551 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"97587_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","volume":"307","author":"R Thadhani","year":"2012","unstructured":"Thadhani, R. et al. Vitamin D therapy and cardiac structure and function n in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307, 674\u2013684 (2012).","journal-title":"JAMA"},{"key":"97587_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1681\/ASN.2014040414","volume":"26","author":"SM Moe","year":"2015","unstructured":"Moe, S. M. et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J. Am. Soc. Nephrol. 26, 1466\u20131475 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"97587_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5414\/CN106965","volume":"76","author":"JM Fraz\u00e3o","year":"2011","unstructured":"Fraz\u00e3o, J. M. et al. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clin. Nephrol. 76, 233\u2013243 (2011).","journal-title":"Clin. Nephrol."},{"key":"97587_CR22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/0886022X.2018.1562356","volume":"41","author":"P Susantitaphong","year":"2019","unstructured":"Susantitaphong, P. et al. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Ren. Fail. 41, 326\u2013333 (2019).","journal-title":"Ren. Fail."},{"key":"97587_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5414\/CNP68010","volume":"68","author":"J Sterrett","year":"2007","unstructured":"Sterrett, J. et al. Cinacalcet HCI (Sensipar\/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin. Nephrol. 68, 10 (2007).","journal-title":"Clin. Nephrol."},{"key":"97587_CR24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","volume":"3","author":"S Fishbane","year":"2008","unstructured":"Fishbane, S. et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin. J. Am. Soc. Nephrol. 3, 1718\u20131725 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97587_CR25","first-page":"443","volume":"30","author":"PS Torres","year":"2010","unstructured":"Torres, P. S. et al. Analysis of efficacy and factors that impact the response of secondary hyperparathyroidism to cinacalcet in haemodialysis patients. Nefrologia. 30, 443\u2013451 (2010).","journal-title":"Nefrologia."},{"key":"97587_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1744-9987.2011.00924.x","volume":"15","author":"M Okada","year":"2011","unstructured":"Okada, M. et al. Tertiary hyperparathyroidism resistant to cinacalcet treatment. Ther. Apher. Dial. 15, 33\u201337 (2011).","journal-title":"Ther. Apher. Dial."},{"key":"97587_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/01213011-200501000-00005","volume":"15","author":"HM Rothe","year":"2005","unstructured":"Rothe, H. M., Shapiro, W. B., Sun, W. Y. & Chou, S.-Y. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl. Pharmacogenet. Genom. 15, 29\u201334 (2005).","journal-title":"Pharmacogenet. Genom."},{"key":"97587_CR28","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.2147\/DDDT.S103370","volume":"10","author":"S Jeong","year":"2016","unstructured":"Jeong, S. et al. Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. Drug Des. Dev. Ther. 10, 2211 (2016).","journal-title":"Drug Des. Dev. Ther."},{"key":"97587_CR29","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.2215\/CJN.11141016","volume":"12","author":"SM Moe","year":"2017","unstructured":"Moe, S. M. et al. Calcium-sensing receptor genotype and response to cinacalcet in patients undergoing hemodialysis. Clin. J. Am. Soc. Nephrol. 12, 1128\u20131138 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97587_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.beem.2013.02.006","volume":"27","author":"EM Brown","year":"2013","unstructured":"Brown, E. M. Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 27, 333\u2013343 (2013).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"97587_CR31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/jpet.103.057273","volume":"308","author":"EF Nemeth","year":"2004","unstructured":"Nemeth, E. F. et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308, 627\u2013635 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"97587_CR32","doi-asserted-by":"publisher","first-page":"29712","DOI":"10.1074\/jbc.273.45.29712","volume":"273","author":"L Gama","year":"1998","unstructured":"Gama, L. & Breitwieser, G. E. A carboxyl-terminal domain controls the cooperativity for extracellular Ca2+ activation of the human calcium sensing receptor: A study with receptor-green fluorescent protein fusions. J. Biol. Chem. 273, 29712\u201329718 (1998).","journal-title":"J. Biol. Chem."},{"key":"97587_CR33","doi-asserted-by":"publisher","first-page":"34880","DOI":"10.1074\/jbc.M100784200","volume":"276","author":"G Hj\u00e4lm","year":"2001","unstructured":"Hj\u00e4lm, G., MacLeod, R. J., Kifor, O., Chattopadhyay, N. & Brown, E. M. Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase. J. Biol. Chem. 276, 34880\u201334887 (2001).","journal-title":"J. Biol. Chem."},{"key":"97587_CR34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/sj.ki.5002156","volume":"71","author":"G Vezzoli","year":"2007","unstructured":"Vezzoli, G. et al. R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int. 71, 1155\u20131162 (2007).","journal-title":"Kidney Int."},{"key":"97587_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1530\/EJE-13-0441","volume":"169","author":"G Han","year":"2013","unstructured":"Han, G. et al. Clinical phenotypes of Chinese primary hyperparathyroidism patients are associated with the calcium-sensing receptor gene R990G polymorphism. Eur. J. Endocrinol. 169, 629\u2013638 (2013).","journal-title":"Eur. J. Endocrinol."},{"key":"97587_CR36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/j.1582-4934.2007.00096.x","volume":"11","author":"J Hu","year":"2007","unstructured":"Hu, J. & Spiegel, A. M. Structure and function of the human calcium-sensing receptor: Insights from natural and engineered mutations and allosteric modulators. J. Cell Mol. Med. 11, 908\u2013922 (2007).","journal-title":"J. Cell Mol. Med."},{"key":"97587_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0140-6736(98)06434-4","volume":"353","author":"DE Cole","year":"1999","unstructured":"Cole, D. E. et al. A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations. Lancet 353, 112\u2013115 (1999).","journal-title":"Lancet"},{"key":"97587_CR38","doi-asserted-by":"publisher","first-page":"994","DOI":"10.4161\/cbt.9.12.11689","volume":"9","author":"GG Schwartz","year":"2010","unstructured":"Schwartz, G. G., John, E. M., Rowland, G. & Ingles, S. A. Prostate cancer in African\u2013American men and polymorphism in the calcium-sensing receptor. Cancer Biol. Ther. 9, 994\u2013999 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"97587_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1530\/eje.1.02286","volume":"155","author":"S Corbetta","year":"2006","unstructured":"Corbetta, S. et al. R990G polymorphism of the calcium-sensing receptor and renal calcium excretion in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 155, 687\u2013692 (2006).","journal-title":"Eur. J. Endocrinol."},{"key":"97587_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/gfaa195","volume":"36","author":"N Tabibzadeh","year":"2021","unstructured":"Tabibzadeh, N. et al. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrol. Dial. Transplant. 36, 160\u2013169 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"97587_CR41","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/ckj\/sfz021","volume":"12","author":"J Rottembourg","year":"2019","unstructured":"Rottembourg, J. et al. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. Clin. Kidney J. 12, 871\u2013879 (2019).","journal-title":"Clin. Kidney J."},{"key":"97587_CR42","first-page":"467","volume-title":"The Role of Phosphate and Other Factors on the Pathogenesis of Renal osteodystrophy","author":"E Slatopolsky","year":"1977","unstructured":"Slatopolsky, E., Rutherford, W., Martin, K. & Hruska, K. The Role of Phosphate and Other Factors on the Pathogenesis of Renal osteodystrophy 467\u2013475 (Springer, 1977)."},{"key":"97587_CR43","doi-asserted-by":"publisher","first-page":"F1390","DOI":"10.1152\/ajprenal.00262.2006","volume":"292","author":"M Rodriguez","year":"2007","unstructured":"Rodriguez, M. et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am. J. Physiol. Renal Physiol. 292, F1390\u2013F1395 (2007).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"97587_CR44","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1093\/ndt\/gfn338","volume":"23","author":"N Carrillo-L\u00f3pez","year":"2008","unstructured":"Carrillo-L\u00f3pez, N. et al. Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol. Dial. Transplant. 23, 3479\u20133484 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"97587_CR45","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2215\/CJN.01060308","volume":"3","author":"MD Danese","year":"2008","unstructured":"Danese, M. D., Belozeroff, V., Smirnakis, K. & Rothman, K. J. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1423\u20131429 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97587_CR46","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2215\/CJN.07730814","volume":"10","author":"PS Parfrey","year":"2015","unstructured":"Parfrey, P. S. et al. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin. J. Am. Soc. Nephrol. 10, 791\u2013799 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97587_CR47","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","unstructured":"EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482\u20132494 (2012).","journal-title":"N. Engl. J. Med."},{"key":"97587_CR48","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1097\/01.ASN.0000100127.54107.57","volume":"14","author":"DA Goodkin","year":"2003","unstructured":"Goodkin, D. A. et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J. Am. Soc. Nephrol. 14, 3270\u20133277 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"97587_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3349\/ymj.2013.54.2.453","volume":"54","author":"J-K Kim","year":"2013","unstructured":"Kim, J.-K. et al. Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients. Yonsei Med. J. 54, 453\u2013463 (2013).","journal-title":"Yonsei Med. J."},{"key":"97587_CR50","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham, J., Locatelli, F. & Rodriguez, M. Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin. J. Am. Soc. Nephrol. 6, 913\u2013921 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"97587_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11255-016-1446-1","volume":"49","author":"S Rauscher","year":"2017","unstructured":"Rauscher, S. et al. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients. Int. Urol. Nephrol. 49, 325\u2013328 (2017).","journal-title":"Int. Urol. Nephrol."},{"key":"97587_CR52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1440-1797.2010.01398.x","volume":"16","author":"K Kiattisunthorn","year":"2011","unstructured":"Kiattisunthorn, K., Wutyam, K., Indranoi, A. & Vasuvattakul, S. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology 16, 277\u2013284 (2011).","journal-title":"Nephrology"},{"key":"97587_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A.-G. & Buchner, A. G* Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods. 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97587-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97587-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T10:22:50Z","timestamp":1670062970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97587-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97587"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97587-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"18 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18006"}}